Navigation Links
BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
Date:1/8/2009

nd other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current phar
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015   PureTech , a science ... commercializing disruptive products and technologies in the healthcare sector, ... former CEO and Member of the Board of Directors ... "It,s has been a pleasure to know Chris ... we will be working together more closely now," said ...
(Date:2/26/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... develops and commercializes proprietary technologies and products for advanced ... for the fiscal first quarter ended December  31, 2014. ... dollars (CAD), unless otherwise stated. "During ... from our existing customers and add to our sales ...
(Date:2/26/2015)... LAUDERDALE, Fla. , Feb. 26, 2015 ... discussed growth priorities driven by key research advancements and ... segments at today,s Bank of America Merrill Lynch 2015 ... met the challenge of building grain supplies the last ... to continue at the pace of the last decade, ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape is ... arena, Frost & Sullivan will host its 20 th ... MindXchange , March 8 to 10, at the Hilton San ... This event is a platform for ... to discuss industry disruptions and how to succeed in an ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3
... Cambridge, Mass. - February 23, 2012 Engineers at Harvard ... uses optical nanoantennas to obtain precise control of color output. ... fixed color, a single active filter under exposure to different ... The advance has the potential for application in televisions and ...
... and AMSTERDAM, Feb. 23, 2012   Rubicon Genomics, ... pre-analytical processes to improve the capabilities and ... today announced a clinical supply agreement with ... whole genome RNA amplification technology.  Agendia will ...
... Study results published today in the   New - ...   show that 3-year graft survival is significantly greater in all ...   Kidney Transporter compared to those stored in a traditional box ... [1]   The graft survival difference at three years was ...
Cached Biology Technology:Metal nanoparticles shine with customizable color 2Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 2Rubicon Genomics and Agendia Sign Agreement for Use of TransPLEX® Whole Genome RNA Amplification Technology With Symphony™ Cancer Diagnostics 3Machine Preservation Significantly Improves Kidney Transplant Survival Over 3 Years Compared to Traditional box of ice 2Machine Preservation Significantly Improves Kidney Transplant Survival Over 3 Years Compared to Traditional box of ice 3
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is ... the State of Washington,s Department of ... enrollment and central issuance system for driver,s licenses and identification ... project planning and development will start in January 2015, with ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... have made an "a-maize-ing" discovery that could lead to ... new research report published in the March 2010 issue ... scientists used tropical maize from Mexico and Thailand to ... flowering time (called the "photoperiod response"). This discovery may ...
... developed by Japanese scientists may revolutionize how and when ... published online in The FASEB Journal ( ... spinal fluid known to be one of the main ... patients: high molecular weight A-Beta oligomers. This tool, ...
... happens in science that what you throw away turns out ... not for long. The Rice assistant professor in chemical ... in a scaffold, and he discarded the sticky substance secreted ... so I threw the plates away," said Nagrath, then a ...
Cached Biology News:'A-maize-ing' discovery could lead to higher corn yields for food, feed and fuel 2New test takes guesswork out of diagnosing early-stage Alzheimer's disease 2Your fat may help you heal 2
... faster than Bromophenol blue,or methylene blue ... dye migrates with DNA between 10 ... this size,prevents the obscuring of smaller ... of DNA migration.,The Orange G Loading ...
... Polyclonal Antibody Description: ... polyclonal antibody. Detects 70 kDa YAP ... blotting and immunohistochemistry. ... Storage: -20C ...
Rabbit polyclonal to QKI...
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
Biology Products: